A Review on Iron Chelators in Treatment of Iron Overload Syndromes

• Published in: International journal of hematology- oncology and stem cell research Vol. 10; no. 4; pp. 239 - 247
• Main Authors: Mobarra, Naser, Shanaki, Mehrnoosh, Ehteram, Hassan, Nasiri, Hajar, Sahmani, Mehdi, Saeidi, Mohsen, Goudarzi, Mehdi, Pourkarim, Hoda, Azad, Mehdi
• Format: Journal Article
• Language: English
• Published: Iran Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 01.10.2016; Tehran University of Medical Sciences
• Subjects: Chelators; Iron overload; Review; Treatment; Chelators; Iron overload; Treatment
• ISSN: 2008-3009; 2008-2207

Iron chelation therapy is used to reduce iron overload development due to its deposition in various organs such as liver and heart after regular transfusion. In this review, different iron chelators implicated in treatment of iron overload in various clinical conditions have been evaluated using more up-to-date studies focusing on these therapeutic agents. Deferoxamine, Deferiprone and Deferasirox are the most important specific US FDA-approved iron chelators. Each of these chelators has their own advantages and disadvantages, various target diseases, levels of deposited iron and clinical symptoms of the afflicted patients which may affect their selection as the best modality. Taken together, in many clinical disorders, choosing a standard chelator does not have an accurate index which requires further clarifications. The aim of this review is to introduce and compare the different iron chelators regarding their advantages and disadvantages, usage dose and specific applications.